Only 81 of 1,318 patients had persistent disease at three months after treatment; 60 later achieved local control with no further treatment<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Jan. 12, 2023 (HealthDay News) — A magnetic resonance imaging-based image-guided adaptive brachytherapy (MR-IGABT) approach is beneficial for locally advanced cervical cancer, according to a study published online Jan. 4 in the Journal of Clinical Oncology<\/em>.<\/p>\n Maximilian P. Schmid, M.D., from the Medical University of Vienna, and colleagues reported patterns of remission and failure and risk factors for local failure (LF) from the EMBRACE-I study, which involved treatment with external beam radiotherapy, concurrent chemotherapy, and MR-IGABT for locally advanced cervical cancer. Data were included for 1,318 patients with a median follow-up of 52 months.<\/p>\n The researchers found that at three months after the end of treatment, 81 patients had persistent disease; of these patients, 60 achieved local tumor control at six to nine months without further treatment and 21 had progressive disease. In addition, a local recurrence developed after complete remission in 77 patients, comprising a total of 98 LFs. In 90 percent of patients with LF, LFs were located inside the MR-IGABT target volumes. A significant impact on LF was seen in a multivariable analysis for factors such as histology, minimal dose to 90 percent of high-risk clinical target volume (CTVHR<\/sub>), maximum tumor dimension, and CTVHR<\/sub> >45 cm3<\/sup>. A minimal dose to 90 percent of 85 Gy to the CTVHR<\/sub> led to local tumor control of 95 percent at three years postintervention for squamous cell versus 86 percent for adeno\/adenosquamous carcinoma histology.<\/p>\n “This is the first time we have seen that different brachytherapy doses are required for individual parameters such as different histologies or different tumor sizes,” Schmid said in a statement.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n